Experts break down key melanoma data and trends from the 2026 ESMO Congress.
Opinion|Videos|November 8, 2024
From Early Stage to Resistance: ALINA Study Insights and ALK Inhibitor Sequencing Strategies
Panelists discuss the findings from the ALINA study on adjuvant alectinib vs chemotherapy in resected ALK-positive NSCLC, considering how these results may influence early-stage management, sequencing strategies for ALK inhibitors, and the role of resistance mechanisms in treatment decisions.
Advertisement
- Dr Rotow: The ALINA study included exploratory biomarker analyses in patients with resected ALK-positive NSCLC treated with adjuvant alectinib vs chemotherapy. (
Solomon BJ, et al. 2024. ESMO. 1206MO )
- What are your thoughts on these findings, and how might they impact your approach to early-stage ALK-positive NSCLC management?
- What strategies are you currently using for sequencing ALK inhibitors?
- How do resistance mechanisms influence your sequence decisions?
- What data support using lorlatinib in the first-line setting vs reserving it for later lines?
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.
Durvalumab plus BCG is now an approved first-line option for high-risk NMIBC, but better BCG delivery and biomarker-guided selection should shape its use.
The FDA has approved amivantamab and hyaluronidase-lpuj for metastatic head and neck squamous cell carcinoma.
A UCLA-led study suggests routine mammograms or other breast imaging may not benefit women after double mastectomy for DCIS.
Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.
Are we ready to “take that fork in the road” and move palliative/supportive care into routine cancer care?
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
3
Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL
4
Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
5